Serum Level of Neuron-Specific Enolase in Patients with Past Ischemic Stroke

T. D. Hrytsiuk

Abstract


The article presents the results of the examination of 128 patients with past ischemic stroke (on the 4th -5th months after acute cerebrovascular disease).

Enzyme immunoassay for the determination of NSE concentration in blood serum of patients included into the study showed that the median of the distribution of enzyme was 14.3 (5.7; 57.8) ng/ml (р<0.05) compared to 3.8 (3.2; 7.5) in patients of the control group.On the basis of the comparison of serum levels of NSE with the value of total NIHSS, MMSE and МоСА score more significant increase in this parameter was detected in patients with profound neurologic deficit and MCI. The analysis of serum NSE is an informative diagnostic criterion for the evaluation of neuronal damage in the brain leading to the inclusion of detection of NSE in clinical practice to optimize diagnostic procedures in patients with past ischemic stroke.


Keywords


past ischemic stroke; neuron-specific enolase; neurologic deficit; cognitive impairments

Full Text:

PDF

References


Mishchenko TS. Efficacy of treatment of cerebral stroke in the acute phase. Novosti meditsiny i farmatsiyi. 2013;5:3.

Morozova YuA, Kamchatnov PR, Akhmetzhanova LL. Content of protein S-100 and tumor-necrosis factor-alpha in serum of patients with discirculatory encephalopathy. Zhurnal nevrologiyi i psikhiatriyi. 2009;5:53-56.

Nerianova YuN. Diagnostic value of detecting serum concentrations of markers of brain tissue damage within the first days of cerebral infarction. Zaporizkyi medychnyi zhurnal. 2014;6(87):48-51.

Karyakina GM, Nadezhdina MV, Khinko MA, et al. Correlation of neuron-specific enolase level with cerebral blood flow in hemispheric ischemic stroke. Byulleten sibirskoy meditsiny. 2009;1(2):37-42.

Hoon Moon J, Lim S, Won Han J, et al. Carotid intima-media thickness is associated with the progression of cognitive impairment in older adults. Stroke. 2015;46:1024-1030.

Rodríguez-Yáñez M, Sobrino T, Arias S, et al. Early biomarkers of clinical–diffusion mismatch in acute ischemic stroke. Stroke. 2011;42:13-28.

Gilhus NE, Barnes MR, Brainin M. European Handbook of Neurological Management. 2nd ed. Blackwell Publishing Ltd. 2011;1:672.

Stein J, Ning M, Black-Schaffer RM. Comparison of clinical characteristics and functional outcomes of ischemic stroke in different vascular territories. Stroke. 2007;8:2309-14.

Ullberg T, Peterson J, Norrving B. Changes in functional outcome over the first year after stroke: an observational study from the Swedish stroke register. Stroke. 2015;46:389-394.

Chaves ML, Camozzato AL, Ferreira ED. Serum levels of S100B and NSE proteins in Alzheimer’s disease patients. Neuroinflammation. 2010;7:6-15.

Pandey A, Saxena K, Verma M. Correlative study between neuron-specific enolase and blood sugar level in ischemic stroke patients. J. Neurosci. Rural Pract. 2011;2(1):50-54.

Bharosay A, Bharosay VV, Varma M, et al. Correlation of brain biomarker neuron specific enolase (NSE) with degree of disability and neurological worsening in cerebrovascular stroke. Ann Indian Acad Neurol. 2013;16(4):504-508.

Singh HV, Pandey A, Shrivastava AK, et al. Prognostic value of neuron specific enolase and IL-10 in ischemic stroke and its correlation with degree of neurological deficit. Clin Chim Acta. 2013;18:136-138.

Daubin C, Quentin Ch, Allouche S. Serum neuron-specific enolase as predictor of outcome in comatose cardiac-arrest survivors: a prospective cohort study. Cardiovascular Disorders. 2011;3:11-48.


Refbacks

  • There are currently no refbacks.




Copyright (c) 2016 T. D. Hrytsiuk

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


IFNMU Logo

Free counters!